This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug
by Zacks Equity Research
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX's obesity pill lost up to 8.2% in body weight after 28 days.
SRPT Stock Rises 23% in a Year: Time to Buy, Hold or Sell?
by Sundeep Ganoria
The upside in Sarepta's share price can be attributed to the encouraging sales performance of its DMD gene therapy, which has demonstrated blockbuster potential.
Puma Biotechnology Stock Rises 24% in 3 Months: Here's Why
by Zacks Equity Research
Sales of PBYI's sole-marketed drug, Nerlynx exceeded management's expectations in the third quarter. Also, the acquisition of alisertib holds promise.
Roche's Prasinezumab Misses Goal in Parkinson's Disease Study
by Zacks Equity Research
The phase IIb PADOVA study, evaluating Roche's prasinezumab in people with early-stage Parkinson's disease, misses the primary endpoint.
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
by Zacks Equity Research
The phase III EMERGENE study evaluates Sarepta's experimental gene therapy for an ultra-rare form of muscle disorder for which there is no treatment beyond symptom management.
Roche Gets Approval for Vabysmo PFS in EU for Three Retinal Diseases
by Zacks Equity Research
RHHBY wins approval for prefilled syringe of ophthalmology drug Vabysmo for three retinal conditions that can cause blindness.
Regeneron Down 15.5% Year to Date: How to Play the Stock?
by Ekta Bagri
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
Pharma Stock Roundup: LLY's Zepbound Success, FDA Updates for MRK, JNJ
by Kinjel Shah
LLY's Zepbound shows better weight loss than NVO's Wegovy in a study. FDA updates for MRK, RHHBY, JNJ and AZN drugs grab headlines.
FDA Accepts Roche's Columvi sBLA for Expanded Use in Lymphoma
by Zacks Equity Research
The FDA accepts RHHBY's sBLA seeking the label expansion of Columvi to include the treatment of second-line R/R DLBCL for review.
NVCR Stock Up as TTFields Therapy Meets Pancreatic Cancer Study Goals
by Zacks Equity Research
Novocure stock soars 49% as the late-stage study of TTFields therapy for treating pancreatic adenocarcinoma meets the primary endpoint of overall survival.
Here's Why You Should Add Dr. Reddy's Stock to Your Portfolio
by Zacks Equity Research
RDY enjoys a strong foothold in the global generics market due to its deep generic drugs pipeline. Its efforts to strengthen its biosimilars portfolio are commendable.
The Zacks Analyst Blog Highlights Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis
by Zacks Equity Research
Roche, Poseida Therapeutics, Merck, AstraZeneca and Novartis are included in this Analyst Blog.
Pharma Stock Roundup: RHHBY to Buy PSTX, MRK, AZN See Pipeline Success
by Kinjel Shah
RHHBY is set to acquire Poseida. MRK and AZN's late-stage studies for expanded use of new drugs meet their respective goals.
Sarepta Therapeutics Stock Surges 43% YTD: How to Play the Stock?
by Sundeep Ganoria
The rise in SRPT's share price can be attributed to the encouraging sales performance of its recently approved one-shot gene therapy for DMD.
SRPT Inks $11B Licensing Deal With Arrowhead for Rare Gene Therapies
by Zacks Equity Research
Sarepta in-licenses rights to four clinical-stage and three preclinical-stage programs targeting muscle, central nervous system and rare pulmonary disorders.
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
by Zacks Equity Research
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
Prothena Q3 Earnings Beat Estimates, Pipeline Progress in Focus
by Zacks Equity Research
PRTA posts a narrower-than-expected loss in the third quarter. The company also reports encouraging pipeline progress for the quarter.
RHHBY or ABBV: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
RHHBY vs. ABBV: Which Stock Is the Better Value Option?
HALO Beats Q3 Earnings & Sales Estimates, Raises '24 View, Stock Up
by Zacks Equity Research
Halozyme reports better-than-expected third-quarter 2024 results. The company raises revenue guidance for 2024. Stock rises in after-hours trading.
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
by Zacks Equity Research
ALNY's Q3 loss per share matches the Zacks Consensus Estimate and revenues miss the same due to lower collaboration revenues. The stock falls 5.3%.
Biogen Beats on Q3 Earnings & Sales, Raises '24 EPS View
by Zacks Equity Research
BIIB's Q3 earnings and sales beat estimates. The company raises its EPS guidance for 2024 by 35 cents.
AbbVie Trumps Q3 Earnings & Sales Estimates, Raises '24 EPS View
by Zacks Equity Research
ABBV's third-quarter 2024 earnings and sales beat estimates. The company increases the EPS guidance on encouraging product sales for immunology drugs.
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
by Kinjel Shah
Roche announces third-quarter and nine-month results. Sanofi holds exclusive talks with CD&R to sell a 50% stake in Opella.
Should AbbVie Stock Be in Your Portfolio Pre-Q3 Earnings?
by Sundeep Ganoria
Investor focus will likely be on the sales performance of ABBV's blockbuster immunology drugs, Rinvoq and Skyrizi, when it reports third-quarter results this month.
CTLT Stock Falls as Potential Hindrance to NVO Buyout Deal Increases
by Zacks Equity Research
Catalent stock faces uncertainty as several pharma companies voice concern about potential limited competition following the acquisition, especially in weight-loss drug manufacturing.